University Of Virginia Discovers That SARS-CoV-2 Exposure Causes The Emergence Of Abzymes: Enzyme-Like Antibodies Responsible For PASC Symptoms!

COVID-19 News: In the wake of the COVID-19 pandemic, researchers worldwide have been racing to unravel the intricacies of the SARS-CoV-2 virus, its acute manifestations, and the lingering effects seen in Long COVID patients. Among the many avenues of investigation, one emerging area of interest revolves around the discovery of abzymes - antibodies with enzymatic activity - and their potential role in COVID-19 pathogenesis, particularly in the development of Long COVID.


SARS-CoV-2 Exposure Causes The Emergence Of Abzymes: Enzyme-Like Antibodies Responsible For PASC Symptoms!
Schematic diagram illustrating the hypothesis underlying the study. The SARS-CoV-2 spike protein RBD binds ACE2 on the surface of potential host cells. The RBD has a partial negative image of ACE2. Some antibodies against the RBD may then have a conformation sufficiently like ACE2 to have proteolytic activity similar to the proteolytic activity of ACE2. The hypothesis further suggests that the catalytic activity of some antibodies will have a substrate specificity like ACE2, but because the negative image of RBD present antibodies is imperfect, some antibodies with proteolytic activity will have an altered substrate specificity, potentially affecting multiple proteolytic regulatory cascades.

Unraveling Abzymes: A Novel Perspective
At the forefront of this research is a team led by Dr Steven L. Zeichner at the University of Virginia Health. Their groundbreaking work that is covered in this COVID-19 News report, has shed light on how COVID-19 may prompt the human body to produce antibodies that mimic enzymes critical for physiological functions like blood pressure regulation, blood clotting, and inflammation. These enzyme-like antibodies, termed abzymes, represent a new frontier in understanding the complexities of COVID-19 and its aftermath.
 
The Significance of Abzymes in COVID-19 Complications
Dr Zeichner, a pediatric infectious disease expert, underscores the importance of this discovery in elucidating the underlying mechanisms of COVID-19 complications. He points out that while some COVID-19 patients exhibit severe symptoms, the root causes often remain elusive. Abzymes, if present, could potentially disrupt various physiological processes, leading to a cascade of complications affecting multiple organ systems.
 
Dr Zeichner commented, “Certain individuals with COVID-19 have serious symptoms even in Post COVID stages and we have trouble understanding their cause. We also have a poor understanding of the causes of long COVID. If COVID-19 patients are indeed making abzymes, it is possible that these rogue abzymes could harm many different aspects of their cellular and bodily functions.”
 
The study team propose that targeting abzymes could offer a more effective therapeutic approach, addressing the core pathology rather than merely managing downstream symptoms. This paradigm shift has the potenti al to revolutionize the treatment landscape for COVID-19 and Long COVID, offering hope to millions grappling with the long-term effects of the virus.
 
Exploring the Connection: SARS-CoV-2 and ACE2 Interaction
Central to the understanding of abzymes in COVID-19 is the interaction between the virus, specifically its Spike protein, and the Angiotensin Converting Enzyme 2 (ACE2) receptor on host cells. ACE2 plays a vital role in regulating blood pressure and vascular function. The researchers hypothesized that antibodies produced in response to the Spike protein might mimic ACE2 and possess enzymatic activity akin to ACE2.
 
The study's findings validated this hypothesis, suggesting that abzymes generated in response to COVID-19 could interfere with normal physiological regulation, contributing to the development of complications seen in COVID-19 patients, including those experiencing Long COVID.
 
Implications for Long COVID and Vaccine Responses
The discovery of abzymes has significant implications for understanding Long COVID, a condition characterized by persistent symptoms long after the acute phase of COVID-19. Studies have linked Long COVID to dysregulation in coagulation, inflammation, and other physiological processes. If abzymes produced in Long COVID patients activate proteins involved in these systems, it could explain the persistence of symptoms even after the initial infection has cleared.
 
Furthermore, the research sheds light on rare side effects associated with COVID-19 vaccination. By understanding the mechanisms underlying these adverse events, researchers can refine vaccine strategies and enhance safety profiles, contributing to more effective vaccination campaigns globally.
 
Understanding Long COVID: Symptoms, Diagnosis, and Treatment
Long COVID, also known as Post-Acute Sequelae of SARS-CoV-2 infection (PASC), presents a complex clinical picture. Symptoms range from fatigue and respiratory issues to neurological impairments and cardiovascular manifestations. Diagnosis is challenging due to the absence of specific tests, relying instead on patient history and symptom evaluation.
 
Current treatment strategies for Long COVID focus on symptom management, rehabilitation programs, and supportive care. However, the discovery of abzymes offers a potential target for future therapies aimed at addressing the underlying pathophysiology of Long COVID, potentially improving outcomes for affected individuals.
 
Exploring Abzymes' Role in COVID-19 Pathogenesis
In their study, researchers at the University of Virginia Health identified ACE-2-like enzymatic activity associated with immunoglobulin in COVID-19 patients. This finding provided valuable insights into the mechanisms underlying COVID-19 pathogenesis and the potential role of abzymes in driving disease progression.

The study's results suggest that some COVID-19 patients develop antibodies with abzyme-like activity capable of cleaving substrates related to ACE2 function. This discovery has implications for understanding the diverse clinical features of COVID-19, including inflammatory processes, coagulopathies, and blood pressure dysregulation.
 
Looking Ahead: The Future of Abzyme Research
While the study represents a significant breakthrough, Dr Zeichner emphasizes that abzyme research is still in its early stages. Similar enzymatic antibodies have been observed in other viral infections, suggesting broader implications beyond COVID-19. Future research directions include studying the specific activities of abzymes, analyzing patient responses to COVID-19 with and without Long COVID, and exploring potential therapeutic interventions targeting abzymes.
 
These efforts are crucial in developing a comprehensive understanding of COVID-19 and advancing precision medicine approaches tailored to individual patient profiles. By unraveling the mysteries of abzyme-mediated pathogenesis, researchers aim to improve patient outcomes, advance treatment strategies, and mitigate the long-term impact of the pandemic on global health.
 
Dr Zeichner told Thailand Medical News, “Our study teams now need to analyze pure versions of antibodies with enzymatic activity to see how abzymes may work in more detail, and we need to study patients who have had COVID-19 who did and did not develop long COVID. There is a lot more work to do, but I think we have made a good start in developing a new understanding of this challenging disease that has caused so much distress and death around the world.”
 
Conclusion: A Path Forward in COVID-19 Research
As research into abzymes and COVID-19 continues, there is optimism regarding the development of targeted therapies that address the root causes of COVID-19 complications, including Long COVID. By unraveling the mysteries of abzyme-mediated pathogenesis, researchers aim to improve patient outcomes, advance treatment strategies, and mitigate the long-term impact of the pandemic on global health.
 
The journey towards effective therapies for COVID-19 and Long COVID is ongoing, driven by scientific curiosity, collaborative efforts, and a shared commitment to combating this unprecedented health crisis. Through continued research and innovation, the medical community strives to transform our understanding of viral diseases and pave the way for a healthier, resilient future.
 
The study findings were published in the peer reviewed journal: mBio
https://journals.asm.org/doi/10.1128/mbio.00541-24
 
For the latest COVID-19 News, keep on logging to Thailand Medical News.